Charles River Laboratories International is positioned for growth driven by its Research Models and Services business and broader CRADL adoption, though soft biopharma demand and currency swings remain headwinds. The company completed the divestiture of its CDMO and Cell Solutions businesses on May 6, 2026, as part of a portfolio reshaping to focus on differentiated scientific capabilities. First-quarter 2026 organic revenues declined 1.5%, reflecting pressure in RMS and discovery services, while foreign currency translation added 2.8% to reported revenues, partially masking the underlying decline. Charles River exited the quarter with cash and cash equivalents of 191.8 million dollars and no short-term debt, and repurchased 200 million dollars of stock under a 1.0 billion dollar authorization. The Zacks Consensus Estimate for 2026 earnings is 11.05 dollars per share on revenues of 3.83 billion dollars, implying a 4.5% revenue decline from the prior year.
Charles River LaboratoriesFirst-quarter 2026 organic revenues declined 1.5%, reflecting pressure in RMS and discovery services due to soft biopharma demand
Integra LifeSciences Holdings
Align Technology Inc
Globus Medical